Clinical Trial Update: Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU) [Phase 2]

View source ↗

Summary

Phase 2 trial update on rAvPAL-PEG for phenylketonuria assessing safety, tolerability, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phenylketonuria

Drugs mentioned

• rAvPAL-PEG (recombinant phenylalanine ammonia-lyase enzyme PEGylated)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Phenylketonuria | Phase 2 | Status: COMPLETED | Results posted: 2019-02-26